Literature DB >> 33782335

Impact of Radiation on Cardiovascular Outcomes in Older Resectable Esophageal Cancer Patients With Medicare.

Reith R Sarkar1,2, Ahmadreza Hatamipour1,2, Neil Panjwani3, P Travis Courtney1,2, Daniel R Cherry1,2, Mia A Salans1,2, Anthony T Yip1,2, Brent S Rose1,2, Daniel R Simpson1,2, Matthew P Banegas4, James D Murphy1,2.   

Abstract

OBJECTIVES: Preoperative radiotherapy improves outcomes for operable esophageal cancer patients, though the proximity of the heart to the esophagus puts patients at risk of radiation-induced cardiovascular disease. This study characterizes the impact of radiotherapy and different radiation techniques on cardiovascular morbidity among a cohort of esophageal cancer patients.
MATERIALS AND METHODS: We identified 1125 patients aged 65 and older diagnosed between 2000 and 2011 with esophageal cancer who received surgery alone, or surgery preceded by either preoperative chemotherapy or preoperative chemoradiation from the Surveillance Epidemiology and End Results (SEER)-Medicare database. We used Medicare claims to identify severe perioperative and late cardiovascular events. Multivariable logistic regression and Fine-Gray models were used to determine the effect of presurgery treatment on the risk of perioperative and late cardiovascular disease.
RESULTS: Preoperative chemotherapy or chemoradiation did not significantly increase the risk of perioperative cardiovascular complications compared with surgery alone. Patients treated with preoperative chemoradiation had a 36% increased risk of having a late cardiovascular event compared with patients treated with surgery alone (subdistribution hazard ratio [SDHR]: 1.36; P=0.035). There was no significant increase in late cardiovascular events among patients treated with preoperative chemotherapy (SDHR: 1.18; P=0.40). Among patients treated with preoperative chemoradiation, those receiving intensity modulated radiotherapy had a 68% decreased risk of having a late cardiovascular event compared with patients receiving conventional radiation (SDHR: 0.32; P=0.007).
CONCLUSIONS: This study demonstrates an increased risk of cardiovascular complications among operative esophageal cancer patients treated with preoperative chemoradiation, though these risks might be reduced with more cardioprotective radiation techniques such as intensity modulated radiotherapy.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33782335      PMCID: PMC8141011          DOI: 10.1097/COC.0000000000000815

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.787


  53 in total

1.  Future directions in esophageal cancer therapy.

Authors:  Ori Wald; Brandon Smaglo; Henry Mok; Shawn S Groth
Journal:  Ann Cardiothorac Surg       Date:  2017-03

2.  Myocardial damage in breast cancer patients treated with adjuvant radiotherapy: a prospective study.

Authors:  G Gyenes; T Fornander; P Carlens; U Glas; L E Rutqvist
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-11-01       Impact factor: 7.038

3.  A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients.

Authors:  Scott C Lester; Steven H Lin; Michael Chuong; Neha Bhooshan; Zhongxing Liao; Andrea L Arnett; Sarah E James; Jaden D Evans; Grant M Spears; Ritsuko Komaki; Michael G Haddock; Minesh P Mehta; Christopher L Hallemeier; Kenneth W Merrell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-20       Impact factor: 7.038

Review 4.  Cancer drugs and the heart: importance and management.

Authors:  Thomas M Suter; Michael S Ewer
Journal:  Eur Heart J       Date:  2012-07-12       Impact factor: 29.983

5.  Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Jaffer A Ajani; Thomas A D'Amico; David J Bentrem; Joseph Chao; Carlos Corvera; Prajnan Das; Crystal S Denlinger; Peter C Enzinger; Paul Fanta; Farhood Farjah; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; Stephen Leong; Quan P Ly; Kristina A Matkowskyj; Michael McNamara; Mary F Mulcahy; Ravi K Paluri; Haeseong Park; Kyle A Perry; Jose Pimiento; George A Poultsides; Robert Roses; Vivian E Strong; Georgia Wiesner; Christopher G Willett; Cameron D Wright; Nicole R McMillian; Lenora A Pluchino
Journal:  J Natl Compr Canc Netw       Date:  2019-07-01       Impact factor: 11.908

6.  3D-conformal RT, fixed-field IMRT and RapidArc, which one is better for esophageal carcinoma treated with elective nodal irradiation.

Authors:  D Wang; Y Yang; J Zhu; B Li; J Chen; Y Yin
Journal:  Technol Cancer Res Treat       Date:  2011-10

7.  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.

Authors:  Anthony V D'Amico; James W Denham; Juanita Crook; Ming-Hui Chen; Samuel Z Goldhaber; David S Lamb; David Joseph; Keen-Hun Tai; Shawn Malone; Charles Ludgate; Allison Steigler; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2007-06-10       Impact factor: 44.544

8.  Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer.

Authors:  Steven H Lin; Lu Wang; Bevan Myles; Peter F Thall; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani; James D Cox; Ritsuko Komaki; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-03       Impact factor: 7.038

Review 9.  Radiation-associated valvular disease.

Authors:  R G Carlson; W R Mayfield; S Normann; J A Alexander
Journal:  Chest       Date:  1991-03       Impact factor: 9.410

10.  Analysis of Intensity-Modulated Radiation Therapy (IMRT), Proton and 3D Conformal Radiotherapy (3D-CRT) for Reducing Perioperative Cardiopulmonary Complications in Esophageal Cancer Patients.

Authors:  Ted C Ling; Jerry M Slater; Prashanth Nookala; Rachel Mifflin; Roger Grove; Anh M Ly; Baldev Patyal; Jerry D Slater; Gary Y Yang
Journal:  Cancers (Basel)       Date:  2014-12-05       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.